Status:

NOT_YET_RECRUITING

Methamphetamine Use Disorder Support in Heart Failure Pilot Study

Lead Sponsor:

University of Southern California

Collaborating Sponsors:

Los Angeles General Medical Center

Conditions:

Heart Failure

Methamphetamine Use Disorder

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Heart failure (HF) affects over 6 million people in the US and is a major cause of both hospital admissions and death. HF has many causes and contributing factors. One of the most aggressive forms of ...

Detailed Description

Prospective, open-label, single-arm study to evaluate the feasibility and preliminary efficacy of a multidisciplinary HF clinic which integrates MUD management along with standard-of-care guideline di...

Eligibility Criteria

Inclusion

  • Heart failure diagnosis meeting universal definition criteria with left ventricular ejection fraction ≤ 40%
  • Active methamphetamine use and stated desire to cease (confirmed by patient self-reported history of active use and /or positive urine toxicology obtained as part of routine patient care); physician verifying patients meets criteria for MUD.
  • Age 18 years or older
  • Empaneled to LA General Medical Center/DHS
  • Able to provide informed consent (translated consent forms will be used for non-English speakers)

Exclusion

  • Polysubstance use (excluding tobacco and marijuana)
  • Documented history of alcohol use disorder (DSM-5) or alcohol dependence (ICD-11). Intermittent alcohol use below these thresholds (e.g. social use) is not an exclusion.
  • Cardiogenic shock requiring mechanical circulatory support at time of presentation
  • Acute coronary syndrome, acute pulmonary embolism, or hemodynamically significant arrhythmia on admission
  • Pregnancy
  • Acute psychiatric condition requiring immediate treatment or significantly impairing their ability to provide informed consent or participate in study procedures

Key Trial Info

Start Date :

November 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2026

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT07211724

Start Date

November 1 2025

End Date

July 31 2026

Last Update

October 8 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Los Angeles General Medical Center

Los Angeles, California, United States, 90089

2

University of Southern California, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences

Los Angeles, California, United States, 90089